子宫内膜癌市场规模、份额、成长分析、按癌症类型、按治疗方法、按诊断方法、按阶段、按最终用途、按地区 - 行业预测，2025 年至 2032 年

预计 2023 年全球子宫内膜癌市场规模将达到 286.9 亿美元，将从 2024 年的 301.0 亿美元成长到 2032 年的 441.3 亿美元，预测期内（2025-2032 年）的复合年增长率为 4.9%。

随着发病率上升、认识度提高和医疗保健基础设施加强，全球子宫内膜癌市场正在经历强劲增长。分子分析和基因检测等诊断工具的创新正在带来更精确和个人化的治疗方案。随着标靶治疗、免疫疗法和联合治疗的出现以及治疗效果的改善，市场正在进一步扩大。基因组分析和液态切片等进步有助于更早发现和发展个人化治疗方法。然而，治疗费用高、获得先进医疗服务的机会有限以及迫切需要有效的早期检测方法等挑战仍然是解决子宫内膜癌全球影响的重大障碍。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

子宫内膜癌市场规模（依癌症类型）

• 市场概况
• 子宫内膜癌
  • 腺癌
  • 癌症肉瘤
  • 鳞状细胞癌
  • 其他类型癌症
• 子宫肉瘤

子宫内膜癌市场规模（依治疗方法）

• 市场概况
• 外科手术
• 化疗
• 放射治疗
• 荷尔蒙疗法
• 标靶治疗
• 免疫疗法

子宫内膜癌市场规模（依诊断方法）

• 市场概况
• 切片检查
• 超音波
• 子宫镜检查
• 电脑断层扫描
• 其他诊断方法

子宫内膜癌市场规模（按阶段）

• 市场概况
• 第一阶段
• 第二阶段
• 第三阶段
• 第四阶段

子宫内膜癌市场规模（依最终用途划分）

• 市场概况
• 医院
• 癌症中心
• 门诊手术中心

子宫内膜癌市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• GlaxoSmithKline plc（GSK）（United Kingdom）
• Merck & Co., Inc.（United States）
• Notable Product：Keytruda（pembrolizumab）
• AstraZeneca plc（United Kingdom）
• Notable Product：Imfinzi（durvalumab）
• Novartis AG（Switzerland）
• Pfizer Inc.（United States）
• F. Hoffmann-La Roche AG（Switzerland）
• Bristol Myers Squibb Company（United States）
• Karyopharm Therapeutics Inc.（United States）
• Siemens Healthineers AG（Germany）
• Takeda Pharmaceutical Company Limited（Japan）
• Incyte Corporation（United States）
• Context Therapeutics Inc.（United States）
• Evergreen Therapeutics, Inc.（United States）
• Sysmex Corporation（Japan）
• Gilead Sciences, Inc.（United States）
• Johnson & Johnson（United States）
• AbbVie Inc.（United States）
• Sanofi SA（France）

结论和建议

Global Endometrial Cancer Market size was valued at USD 28.69 billion in 2023 and is poised to grow from USD 30.1 billion in 2024 to USD 44.13 billion by 2032, growing at a CAGR of 4.9% during the forecast period (2025-2032).

The global endometrial cancer market is experiencing robust growth, fueled by rising incidence rates, heightened awareness, and enhanced healthcare infrastructure. Innovations in diagnostic tools, including molecular profiling and genetic testing, are leading to more precise and personalized treatment options. The market is further expanding due to the emergence of targeted therapies, immunotherapies, and combination treatment modalities that provide improved outcomes. Advancements such as genomic profiling and liquid biopsies facilitate early detection and tailored treatment approaches. Nevertheless, challenges like high treatment costs, limited access to advanced healthcare services, and the pressing need for effective early detection methods continue to pose significant hurdles in addressing the global impact of endometrial cancer.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Endometrial Cancer market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Endometrial Cancer Market Segmental Analysis

Global Endometrial Cancer Market is segmented by Cancer Type, Treatment, Diagnosis Method, Stage, End Use and region. Based on Cancer Type, the market is segmented into Endometrial carcinoma and Uterine sarcoma. Based on Treatment, the market is segmented into Surgery, Chemotherapy, Radiation therapy, Hormone therapy, Targeted therapy and Immunotherapy. Based on Diagnosis Method, the market is segmented into Biopsy, Pelvic Ultrasound, Hysteroscopy, CT Scan and Other Diagnosis Methods. Based on Stage, the market is segmented into Stage I, Stage II, Stage III and Stage IV. Based on End Use, the market is segmented into Hospitals, Cancer centers and Ambulatory surgical centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Endometrial Cancer Market

The global endometrial cancer market is significantly driven by the rising incidence of this prevalent gynecological cancer. Factors such as obesity, hormonal imbalances, and diabetes are contributing to a steady increase in cases, prompting a growing need for effective diagnostic and therapeutic options. This heightened demand for solutions not only accelerates market growth but also emphasizes the importance of advancements in medical technology and enhanced screening methods. These innovations facilitate early detection and treatment of endometrial cancer, ultimately leading to improved patient outcomes and further stimulating investments in healthcare infrastructure to combat this escalating health concern.

Restraints in the Global Endometrial Cancer Market

One significant challenge facing the global endometrial cancer market is the combination of high treatment costs and restricted healthcare accessibility, particularly in developing countries. The financial burden associated with treatment options like surgeries, chemotherapy, and radiation therapy can be overwhelming for many patients, especially those lacking sufficient health insurance or financial resources. Furthermore, in various regions, inadequate healthcare infrastructure, including a shortage of diagnostic services and specialized professionals, complicates the timely and effective treatment of endometrial cancer. To enhance patient outcomes worldwide, it is essential to tackle these obstacles by improving both the affordability and accessibility of quality healthcare.

Market Trends of the Global Endometrial Cancer Market

The Global Endometrial Cancer market is experiencing a notable trend of increased collaborations and partnerships among pharmaceutical companies and research institutions, aimed at expediting drug development and clinical trials. This strategic synergy enhances the focus on innovative diagnostics and the introduction of novel therapeutic options, ultimately translating into improved patient outcomes. Moreover, the rising incidence of endometrial cancer and heightened awareness surrounding women's health are driving the demand for advanced treatment solutions. As stakeholders prioritize research investments and regulatory approvals, this collaborative landscape is likely to foster a dynamic market, positioning it for accelerated growth in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Endometrial Cancer Market Size by Cancer Type & CAGR (2025-2032)

• Market Overview
• Endometrial carcinoma
  • Adenocarcinoma
  • Carcinosarcoma
  • Squamous Cell Carcinoma
  • Other Types of Cancer
• Uterine sarcoma

Global Endometrial Cancer Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Surgery
• Chemotherapy
• Radiation therapy
• Hormone therapy
• Targeted therapy
• Immunotherapy

Global Endometrial Cancer Market Size by Diagnosis Method & CAGR (2025-2032)

• Market Overview
• Biopsy
• Pelvic Ultrasound
• Hysteroscopy
• CT Scan
• Other Diagnosis Methods

Global Endometrial Cancer Market Size by Stage & CAGR (2025-2032)

• Market Overview
• Stage I
• Stage II
• Stage III
• Stage IV

Global Endometrial Cancer Market Size by End Use & CAGR (2025-2032)

• Market Overview
• Hospitals
• Cancer centers
• Ambulatory surgical centers

Global Endometrial Cancer Market Size & CAGR (2025-2032)

• North America (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
  • US
  • Canada
• Europe (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• GlaxoSmithKline plc (GSK) (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Notable Product: Keytruda (pembrolizumab)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Notable Product: Imfinzi (durvalumab)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Karyopharm Therapeutics Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Context Therapeutics Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evergreen Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations